Seòmar agus comataidhean

Forestry and Land Scotland sells the venison (deer carcasses in skin) produced on Scotland’s national forests and land to Approved Game Meat Handling Establishments (AGHE), not a ‘wholesaler’.

The volume sold to AGHEs broken down by financial year as follows:

Registration opened on 15 June 2017, and delivery of Baby Boxes nationwide began on 15 August 2017 for all babies born and resident in Scotland.

We are unable to give the number of Baby Boxes delivered in the Dundee local authority area as we only record numbers of Baby Boxes distributed by Health Board area. We can provide the number of boxes delivered in Tayside Health Board.

The total number issued in NHS Tayside up to 3 February 2023 is 17,735 Baby Boxes.

The total breakdown is provided below:

The Children, Young People, Families and Adult Learners (CYPFAL) third sector fund received a significant number of applications from a wide range of organisations totalling £121.8 million of requested funding over the two years, far exceeding the amount of funding available. While we had planned to inform applicants of funding decisions by 31 December 2022, unfortunately this was not possible as more time was required to fully consider all information related to the CYPFAL assessment process.

To support organisations currently funded through the Children, Young People and Families Early Intervention & Adult Learning & Empowering Communities (CYPFEI & ALEC) third sector fund, the Scottish Government is maintaining funding to the total value of £3.6m, bridging the period of the three month extension and consideration of CYPFAL applications.

Additionally, the CYPFEI & ALEC fund administrator, The Corra Foundation, are available to organisations who applied to the Children, Young People, Families and Adult Learning third sector fund to offer non-financial support by providing links to third sector interfaces to help identify any alternative funding streams.

The analysis was published on 3 March and can be found here - https://www.gov.scot/publications/energy-system-transition-independent-analysis/ .

This publication is an independent report, reviewed by an independent panel, which provides a significant volume of evidence and analysis and will contribute to our understanding of the opportunities and challenges in energy transition. To allow stakeholders to fully consider this material before responding, the consultation period for the draft ESJTP has been extended by 5 weeks, and will now close on 9 May.

To date, we have been laying the foundations to deliver on Scotland’s first National Transitions to Adulthood Strategy to support disabled young people as they make the transition to young adult life, through research and engagement.

The scope, vision, aims and national priorities for the strategy will now be developed through external stakeholder engagement and wider consultation. Staffing costs for this work will be met from our operating costs budget for 2023-24.

The costs associated with the implementation of the Strategy will be determined by the actions that are developed and ultimately included, once agreed.

The Scottish Government has sought advice from the Scottish Fire and Rescue Service regarding their views on making changes to muirburn legislation.

The Scottish Government expects health care professionals to deliver high quality person-centred care in line with best practice guidance. The NICE (National Institute for Health and Care Excellence) guideline on management of rheumatoid arthritis in adults (NG100) is available on its website: www.nice.org.uk. The Scottish Intercollegiate Guidelines Network (SIGN) guideline on management of psoriatic arthritis in adults (SIGN 121) is available on its website: www.sign.ac.uk.

The Scottish Government is committed to ensuring that people living in Scotland with long term conditions such as rheumatoid arthritis are able to access the best possible care and support.

The Scottish Government is working to ensure an overarching approach for advanced therapy medicinal products (ATMPs) is in place in order to facilitate a ‘once for Scotland’ approach, where possible. We recognise that there are wide-ranging implications and challenges for the managed introduction of these personalised medicines, and are committed to adopting a co-ordinated approach where practical. We are working across Government to develop our understanding of the future direction for this area of medicines policy, including associated genomic testing and service planning implications for the NHS.

In Scotland, the Scottish Medicines Consortium (SMC) appraises the clinical and cost-effectiveness of newly-licensed medicines. Following receipt of a submission from the manufacturer, the SMC carries out an appraisal of the medicine and then determines whether it should be accepted for routine use within the NHS in Scotland. The SMC appraisal is undertaken independently of Scottish Ministers and is based on the clinical and cost-effectiveness of the medicine at a population level. Following the appraisal process, the SMC publishes advice for NHS Scotland Health Boards to consider. The decision to prescribe a medicine for a patient, and which medicine to prescribe, is entirely for the clinician in charge of a patient’s care, having taken into account the patient’s clinical condition and any relevant clinical guidance.